SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 7, 2005
| Savient Pharmaceuticals, Inc. |
|
| (Exact name of registrant as specified in charter) |
| | | |
| Delaware | 0-15313 | 13-3033811 |
|
|
|
(State or other juris-
diction of incorporation | (Commission
File Number) | (IRS Employer
Identification No.) |
| |
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816 |
|
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code: (732) 418-9300
| Not applicable |
|
| (Former name or former address, if changed since last report) |
Item 2.02. Results of Operations and Financial Condition
On November 7, 2005, Savient Pharmaceuticals, Inc. (“Savient”) announced a business update, in which it provided a financial overview for the quarter ended September 30, 2005 and discussed recent strategic developments. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In addition, on November 7, 2005, Savient held a publicly available live webcast discussion of this business overview. The transcript of the November 7, 2005 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements And Exhibits
| | (c) Exhibits | |
| | | |
| | 99.1 | Press release dated November 7, 2005 |
| | | |
| | 99.2 | Transcript dated November 7, 2005 |
| | | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 8, 2005 | SAVIENT PHARMACEUTICALS, INC. |
| | | |
| | By: | /s/ Philip K. Yachmetz |
| | |
|
| | | Philip K. Yachmetz
Senior Vice President, General Counsel and Secretary |
| | | |
EXHIBIT INDEX
| Exhibit No. | Description | |
| | |
| 99.1 | Press release dated November 7, 2005 | |
| | | |
| 99.2 | Transcript dated November 7, 2005 | |
